Barclays Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right at Overweight

Barclays initiated coverage of Ligand Pharmaceuticals Incorporated (OTCPK: LGNDZ) on Sept. 25, 2026, assigning an Overweight recommendation. The update follows other recent analyst actions: on Sept. 24, 2026, HC Wainwright & Co. reiterated a Buy rating, and on Sept. 23, Citigroup maintained a Buy rating. The article also cites consensus figures as of Feb. 24, 2026, showing a target mean and median of $0.00, with a reported consensus target revision of -76.23% from $0.01 recorded on Jan. 14, 2026. For the recommendation period starting Sept. 1, 2026, totals include 7 strong buys, 8 buys, and 1 hold, reflecting a 93.8% positive share.